Ashwani Verma

Stock Analyst at UBS

(3.55)
# 930
Out of 5,044 analysts
91
Total ratings
52.24%
Success rate
5.97%
Average return

Stocks Rated by Ashwani Verma

Avadel Pharmaceuticals
Oct 28, 2025
Downgrades: Neutral
Price Target: $20
Current: $18.59
Upside: +7.58%
Harmony Biosciences Holdings
Oct 15, 2025
Maintains: Buy
Price Target: $50$43
Current: $29.64
Upside: +45.07%
Neurocrine Biosciences
Oct 9, 2025
Maintains: Buy
Price Target: $188$195
Current: $147.38
Upside: +32.31%
United Therapeutics
Sep 29, 2025
Maintains: Buy
Price Target: $560$580
Current: $415.34
Upside: +39.64%
Teva Pharmaceutical Industries
Sep 24, 2025
Maintains: Buy
Price Target: $23$26
Current: $19.78
Upside: +31.45%
Biohaven
Sep 16, 2025
Maintains: Buy
Price Target: $27$26
Current: $17.20
Upside: +51.16%
ACADIA Pharmaceuticals
Sep 9, 2025
Maintains: Buy
Price Target: $36$39
Current: $22.62
Upside: +72.41%
Axsome Therapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $133$144
Current: $133.51
Upside: +7.86%
Exelixis
Jul 30, 2025
Maintains: Neutral
Price Target: $43$38
Current: $40.08
Upside: -5.18%
Immunovant
Jul 28, 2025
Maintains: Neutral
Price Target: $17$18
Current: $21.98
Upside: -18.11%
Maintains: Buy
Price Target: $60$54
Current: $32.57
Upside: +65.80%
Upgrades: Buy
Price Target: $33$42
Current: $31.00
Upside: +35.48%
Maintains: Neutral
Price Target: $61
Current: $91.65
Upside: -33.44%
Maintains: Neutral
Price Target: $47$41
Current: $61.97
Upside: -33.84%
Maintains: Neutral
Price Target: $1.5$1.05
Current: $1.74
Upside: -39.66%
Upgrades: Buy
Price Target: $145$179
Current: $138.13
Upside: +29.59%
Maintains: Buy
Price Target: $106$114
Current: $87.49
Upside: +30.30%
Downgrades: Neutral
Price Target: $28
Current: $36.41
Upside: -23.10%
Maintains: Buy
Price Target: $11$7
Current: $134.24
Upside: -94.79%
Upgrades: Neutral
Price Target: $9$12
Current: $10.29
Upside: +16.62%
Initiates: Buy
Price Target: $15
Current: $1.89
Upside: +693.65%